Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications

Research output: Contribution to journal › Review › Research › peer-review

Standard

Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications. / Gawalko, Monika; Agbaedeng, Thomas A.; Saljic, Arnela; Mueller, Dominik N.; Wilck, Nicola; Schnabel, Renate; Penders, John; Rienstra, Michiel; van Gelder, Isabelle; Jespersen, Thomas; Schotten, Ulrich; Crijns, Harry J. G. M.; Kalman, Jonathan M.; Sanders, Prashanthan; Nattel, Stanley; Dobrev, Dobromir; Linz, Dominik.

In: Cardiovascular Research, Vol. 118, No. 11, 2022, p. 2415–2427.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Gawalko, M, Agbaedeng, TA, Saljic, A, Mueller, DN, Wilck, N, Schnabel, R, Penders, J, Rienstra, M, van Gelder, I, Jespersen, T, Schotten, U, Crijns, HJGM, Kalman, JM, Sanders, P, Nattel, S, Dobrev, D & Linz, D 2022, 'Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications', Cardiovascular Research, vol. 118, no. 11, pp. 2415–2427. https://doi.org/10.1093/cvr/cvab292

APA

Gawalko, M., Agbaedeng, T. A., Saljic, A., Mueller, D. N., Wilck, N., Schnabel, R., Penders, J., Rienstra, M., van Gelder, I., Jespersen, T., Schotten, U., Crijns, H. J. G. M., Kalman, J. M., Sanders, P., Nattel, S., Dobrev, D., & Linz, D. (2022). Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications. Cardiovascular Research, 118(11), 2415–2427. https://doi.org/10.1093/cvr/cvab292

Vancouver

Gawalko M, Agbaedeng TA, Saljic A, Mueller DN, Wilck N, Schnabel R et al. Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications. Cardiovascular Research. 2022;118(11):2415–2427. https://doi.org/10.1093/cvr/cvab292

Author

Gawalko, Monika ; Agbaedeng, Thomas A. ; Saljic, Arnela ; Mueller, Dominik N. ; Wilck, Nicola ; Schnabel, Renate ; Penders, John ; Rienstra, Michiel ; van Gelder, Isabelle ; Jespersen, Thomas ; Schotten, Ulrich ; Crijns, Harry J. G. M. ; Kalman, Jonathan M. ; Sanders, Prashanthan ; Nattel, Stanley ; Dobrev, Dobromir ; Linz, Dominik. / Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications. In: Cardiovascular Research. 2022 ; Vol. 118, No. 11. pp. 2415–2427.

Bibtex

@article{df64293dfabc4ead83debd88402b35dc,
title = "Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications",
abstract = "Recent preclinical and observational cohort studies have implicated imbalances in gut microbiota composition as a contributor to atrial fibrillation (AF). The gut microbiota is a complex and dynamic ecosystem containing trillions of microorganisms, which produces bioactive metabolites influencing host health and disease development. In addition to host-specific determinants, lifestyle-related factors such as diet and drugs are important determinants of the gut microbiota composition. In this review, we discuss the evidence suggesting a potential bidirectional association between AF and gut microbiota, identifying gut microbiota-derived metabolites as possible regulators of the AF substrate. We summarize the effect of gut microbiota on the development and progression of AF risk factors, including heart failure, hypertension, obesity, and coronary artery disease. We also discuss the potential anti-arrhythmic effects of pharmacological and diet-induced modifications of gut microbiota composition, which may modulate and prevent the progression to AF. Finally, we highlight important gaps in knowledge and areas requiring future investigation. Although data supporting a direct relationship between gut microbiota and AF are very limited at the present time, emerging preclinical and clinical research dealing with mechanistic interactions between gut microbiota and AF is important as it may lead to new insights into AF pathophysiology and the discovery of novel therapeutic targets for AF.",
keywords = "Arrhythmia, Atrial fibrillation, Cardiometabolic, Gut microbiota, Metabolites, TRIMETHYLAMINE-N-OXIDE, LIFE-STYLE INTERVENTION, BILE-ACID METABOLISM, INTESTINAL MICROBIOTA, HEART-FAILURE, L-CARNITINE, DIET, INFLAMMATION, ANTIBIOTICS, OVERWEIGHT",
author = "Monika Gawalko and Agbaedeng, {Thomas A.} and Arnela Saljic and Mueller, {Dominik N.} and Nicola Wilck and Renate Schnabel and John Penders and Michiel Rienstra and {van Gelder}, Isabelle and Thomas Jespersen and Ulrich Schotten and Crijns, {Harry J. G. M.} and Kalman, {Jonathan M.} and Prashanthan Sanders and Stanley Nattel and Dobromir Dobrev and Dominik Linz",
year = "2022",
doi = "10.1093/cvr/cvab292",
language = "English",
volume = "118",
pages = "2415–2427",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "11",

}

RIS

TY - JOUR

T1 - Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications

AU - Gawalko, Monika

AU - Agbaedeng, Thomas A.

AU - Saljic, Arnela

AU - Mueller, Dominik N.

AU - Wilck, Nicola

AU - Schnabel, Renate

AU - Penders, John

AU - Rienstra, Michiel

AU - van Gelder, Isabelle

AU - Jespersen, Thomas

AU - Schotten, Ulrich

AU - Crijns, Harry J. G. M.

AU - Kalman, Jonathan M.

AU - Sanders, Prashanthan

AU - Nattel, Stanley

AU - Dobrev, Dobromir

AU - Linz, Dominik

PY - 2022

Y1 - 2022

N2 - Recent preclinical and observational cohort studies have implicated imbalances in gut microbiota composition as a contributor to atrial fibrillation (AF). The gut microbiota is a complex and dynamic ecosystem containing trillions of microorganisms, which produces bioactive metabolites influencing host health and disease development. In addition to host-specific determinants, lifestyle-related factors such as diet and drugs are important determinants of the gut microbiota composition. In this review, we discuss the evidence suggesting a potential bidirectional association between AF and gut microbiota, identifying gut microbiota-derived metabolites as possible regulators of the AF substrate. We summarize the effect of gut microbiota on the development and progression of AF risk factors, including heart failure, hypertension, obesity, and coronary artery disease. We also discuss the potential anti-arrhythmic effects of pharmacological and diet-induced modifications of gut microbiota composition, which may modulate and prevent the progression to AF. Finally, we highlight important gaps in knowledge and areas requiring future investigation. Although data supporting a direct relationship between gut microbiota and AF are very limited at the present time, emerging preclinical and clinical research dealing with mechanistic interactions between gut microbiota and AF is important as it may lead to new insights into AF pathophysiology and the discovery of novel therapeutic targets for AF.

AB - Recent preclinical and observational cohort studies have implicated imbalances in gut microbiota composition as a contributor to atrial fibrillation (AF). The gut microbiota is a complex and dynamic ecosystem containing trillions of microorganisms, which produces bioactive metabolites influencing host health and disease development. In addition to host-specific determinants, lifestyle-related factors such as diet and drugs are important determinants of the gut microbiota composition. In this review, we discuss the evidence suggesting a potential bidirectional association between AF and gut microbiota, identifying gut microbiota-derived metabolites as possible regulators of the AF substrate. We summarize the effect of gut microbiota on the development and progression of AF risk factors, including heart failure, hypertension, obesity, and coronary artery disease. We also discuss the potential anti-arrhythmic effects of pharmacological and diet-induced modifications of gut microbiota composition, which may modulate and prevent the progression to AF. Finally, we highlight important gaps in knowledge and areas requiring future investigation. Although data supporting a direct relationship between gut microbiota and AF are very limited at the present time, emerging preclinical and clinical research dealing with mechanistic interactions between gut microbiota and AF is important as it may lead to new insights into AF pathophysiology and the discovery of novel therapeutic targets for AF.

KW - Arrhythmia

KW - Atrial fibrillation

KW - Cardiometabolic

KW - Gut microbiota

KW - Metabolites

KW - TRIMETHYLAMINE-N-OXIDE

KW - LIFE-STYLE INTERVENTION

KW - BILE-ACID METABOLISM

KW - INTESTINAL MICROBIOTA

KW - HEART-FAILURE

KW - L-CARNITINE

KW - DIET

KW - INFLAMMATION

KW - ANTIBIOTICS

KW - OVERWEIGHT

U2 - 10.1093/cvr/cvab292

DO - 10.1093/cvr/cvab292

M3 - Review

C2 - 34550344

VL - 118

SP - 2415

EP - 2427

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 11

ER -

ID: 317957921